作者
Pablo Umana, Ekkehard Moessner, Peter Bruenker, Gabriele Unsin, Ursula Puentener, Tobias Suter, Roger Grau, Carla Schmidt, Christian Gerdes, Adam Nopora, Monika Patre, Samuel Moser, Peter Sondermann, Luise Wheat, Martin JS Dyer, Sibrand Poppema, Sabine Bauer, Pamela Strein, Thomas Friess, Christian Klein
发表日期
2006/11/16
来源
Blood, The Journal of the American Society of Hematology
卷号
108
期号
11
页码范围
229-229
出版商
American Society of Hematology
简介
Background: Treatment of B-cell non-Hodgkin lymphoma (NHL) with antibodies targeting CD20 in conjunction with combination chemotherapy is standard clinical practice. Two different types of CD20 MAb differing significantly in their mode of CD20 binding and biological activities have been identified (Cragg and Glennie. Blood103: 2738–2743, 2004): type I antibodies, as rituximab, are potent in complement mediated cytotoxicity, whereas type II antibodies, as tositumomab, effectively initiate target cell death via caspase-independent apoptosis with concomitant phosphatidylserine exposure. GA101 is a humanized and optimized, third generation, type II CD20 IgG1 antibody that exhibits enhanced ADCC and superior caspase-independent apotosis induction in comparison with currently available CD20 MAbs.
Material and Methods: GA101 was humanized by grafting CDR sequences from the …
学术搜索中的文章
P Umana, E Moessner, P Bruenker, G Unsin… - 2006